Neuronetics, Inc.
STIM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.38 | 0.20 | 0.12 | 0.05 |
| FCF Yield | -0.49% | -1.63% | -7.61% | -14.71% |
| EV / EBITDA | -23.82 | -41.94 | -29.27 | -11.76 |
| Quality | ||||
| ROIC | -6.00% | -7.18% | -9.02% | -10.03% |
| Gross Margin | 45.87% | 46.60% | 49.22% | 66.21% |
| Cash Conversion Ratio | 0.09 | 0.35 | 1.34 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | 23.33% | 17.87% | 10.35% | 4.72% |
| Free Cash Flow Growth | 76.06% | 78.18% | -98.18% | -49.66% |
| Safety | ||||
| Net Debt / EBITDA | 1.28 | -9.72 | -6.32 | -6.12 |
| Interest Coverage | -3.32 | -4.09 | -5.73 | -6.53 |
| Efficiency | ||||
| Inventory Turnover | 4.67 | 4.12 | 3.99 | 1.79 |
| Cash Conversion Cycle | 13.97 | 41.77 | 51.23 | 16.30 |